focus -WSS

focus

author：hotspot 2025-08-25 07:27:27 - browse：5826

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Activists slam private health insurers over coverage restrictions

focus

WSS

ChatGPT in medicine: STAT answers readers' burning questions

Option Care buys Amedisys in $3.6 billion home care deal

Duchenne breakthrough therapy leaves behind pioneering families

Australia's humpback populations rebound raising hopes of marine scientists

Drug repurposing or repositioning? The language matters

A new study asks: Are we harming blood donors by taking blood?

focus

focus

entertainment

Supreme Court strikes down use of affirmative action

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Guidelines to prevent youth baseball injuries need more muscle

As demand for Covid shots wanes, Moderna seeks its next success

Hepatitis C has a cure — but many Americans still lack access to it

Doctor appointment wait times are getting worse

BioMarin wins approval for gene therapy to treat hemophilia A

Grail is spending more than ever lobbying Congress

How one medical school became remarkably diverse

Inside the fall of star MIT scientist David Sabatini

knowledge

Medicare details structure of new drug price negotiation program

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The cancer drug shortage isn’t new — and neither are the solutions

Activists slam private health insurers over coverage restrictions

Brain 'hot spot' may explain why African Americans feel greater pain

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

focus

hotspot

entertainment

entertainment